Coherus Oncology, Inc. (CHRS) is a Biotechnology company in the Healthcare sector, currently trading at $1.88. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of CHRS = $1,395.48 (+74127.7% from the current price, the stock appears undervalued). Analyst consensus target is CHRS = $6 (+220.2% upside).
Valuation: CHRS trades at a trailing Price-to-Earnings (P/E) of 1.2 (S&P 500 average ~25).
Financials: revenue is $42M, -19.5%/yr average growth. Net income is $170M (loss), growing at -186.1%/yr. Net profit margin is -403.8% (negative). Gross margin is 67.2% (+0.4 pp trend).
Balance sheet: total debt is $40M against $61M equity (Debt-to-Equity (D/E) ratio 0.66, moderate). Current ratio is 1.46 (adequate). Debt-to-assets is 15.6%. Total assets: $258M.
Analyst outlook: 13 / 16 analysts rate CHRS as buy (81%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 33/100 (Fail), Moat 46/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).
